Of inquiry directing the Secretary of Health and Human Services to provide certain documentation to the House of Representatives relating to the negotiation of prices for prescription drugs under the Medicare prescription drug program.
Health Subcommittee, Energy and Commerce Committee
Introduced
In Committee
On Floor
Passed Chamber
Enacted
This resolution directs the Department of Health and Human Services (HHS) to furnish to the House of Representatives any external or internal communications of the White House regarding the implications of imposing certain penalties on drug manufacturers that do not comply with HHS price negotiations under the Medicare prescription drug benefit.
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in House
Referred to the House Committee on Energy and Commerce.
Referred to the Subcommittee on Health.
Subcommittee on Health Discharged.
Ordered to be Reported Adversely by the Yeas and Nays: 31 - 22.
Committee Consideration and Mark-up Session Held.
Placed on the House Calendar, Calendar No. 140.
Reported adversely by the Committee on Energy and Commerce. H. Rept. 117-534.
Introduced in House
Referred to the House Committee on Energy and Commerce.
Referred to the Subcommittee on Health.
Subcommittee on Health Discharged.
Ordered to be Reported Adversely by the Yeas and Nays: 31 - 22.
Committee Consideration and Mark-up Session Held.
Placed on the House Calendar, Calendar No. 140.
Reported adversely by the Committee on Energy and Commerce. H. Rept. 117-534.
Health
Congressional oversightGovernment information and archivesMedicarePrescription drugs
Of inquiry directing the Secretary of Health and Human Services to provide certain documentation to the House of Representatives relating to the negotiation of prices for prescription drugs under the Medicare prescription drug program.
USA117th CongressHRES-1284| House
| Updated: 9/30/2022
This resolution directs the Department of Health and Human Services (HHS) to furnish to the House of Representatives any external or internal communications of the White House regarding the implications of imposing certain penalties on drug manufacturers that do not comply with HHS price negotiations under the Medicare prescription drug benefit.